Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

Charité – Universitätsmedizin Berlin

Germany
1 Trial1 Paper

The MIND Foundation partnered with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals. Charité is affiliated with Humboldt University and Free University Berlin. This partnership sees researchers at the hospital carrying out clinical studies with psilocybin in patients with treatment-resistant depression. Studies also take place concurrently at the Central Institute for Mental Health Mannheim.

Academic Research

1 papers

Published Papers

1

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Mar 18, 2026

Quick Facts

Type
hospital
HQ
Germany
Website
Visit

Collaborated Trials

1
CompletedII

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Start Date
Compounds
Placebo, Psilocybin

Research Papers

1
Open Accessindividual

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

In this triple‑blind, active placebo‑controlled randomised trial (n=144) of adults with treatment‑resistant depression, two 25 mg doses of psilocybin plus adjunct psychotherapy produced clinically meaningful reductions in depressive symptoms on exploratory secondary measures but did not significantly improve the pre‑second‑dose HAMD17 response rate versus nicotinamide.

Published
Journal
JAMA Psychiatry
Authors
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Kirchen, N., Kulakova, E., Kunz, L., Meijer, A., Rohrmoser, B., Wellek, S., Berger, M. M., Gründer, G.